This clinical trial is focused on studying the effects of the medication azithromycin on children aged 1-5 years who are hospitalized with symptoms similar to asthma. Asthma is a condition that affects the airways in the lungs, making it difficult to breathe. The purpose of the study is to see if a three-day treatment with azithromycin can reduce the duration of these asthma-like episodes compared to a placebo. The study aims to replicate previous findings that showed azithromycin could significantly shorten the length of these episodes.

During the trial, children will receive either azithromycin or a placebo for three days. The study will monitor how long the asthma-like symptoms last from the start of the treatment. It will also look at changes in symptom scores, the length of hospital stays, and the need for additional medications like short-acting beta-agonists (SABA) or oral corticosteroids (OCS). The study will also consider whether bacteria in the airways affect the results and assess the economic impact on families, such as days missed from daycare or work.

In addition to azithromycin, the study involves other substances like xanthum gum, sucrose, silica, colloidal anhydrous, aspartame, hydroxypropyl cellulose LF, sodium phosphate dodecahydrate, and titanium dioxide. These substances are used in various forms, such as creams, powders, and tablets, and are administered orally. The trial will help determine the effectiveness of azithromycin in treating asthma-like symptoms in young children and provide insights into the potential benefits and costs associated with this treatment approach.